Arrhythmias & electrophysiology
Left Atrial Appendage Closure in Patients Considered Unsuitable for Oral Anticoagulation: Randomized Outcomes Through 5 Years in ASAP-TOO
Primary result · Primary effectiveness endpoint: ischemic stroke or systemic embolism; primary safety endpoint: death, ischemic stroke, systemic embolism, or 7-day device/procedure-related events requiring major interventionResult — go to the resultHazard ratio 0.73 95% CI 0.35–1.52- prematurely terminated
Authors' conclusion
In this prematurely terminated and underpowered trial, LAAC implantation was successful, with acceptable safety. Long-term estimates with LAAC were numerically favorable for thromboembolism but imprecise, while early bleeding was increased with the mandated antiplatelet regimen. These findings should be interpreted as exploratory and integrated with contemporary evidence and shared decision making. (Assessment of the WATCHMAN Device in Patients Unsuitable for Oral Anticoagulation [ASAP-TOO]; NCT02928497).
Study context
- Population
- Patients with atrial fibrillation, CHA2DS2-VASc score ≥2, and oral anticoagulation (OAC) unsuitabilityrandomized, target enrollment was 888 patients
- Participants
- 481 patients
- Comparison
- Left atrial appendage closure (LAAC) with a Watchman device vs control treatment
- LAACn = 320
- Control treatmentn = 161reference
- Primary endpoint
- Primary effectiveness endpoint: ischemic stroke or systemic embolism; primary safety endpoint: death, ischemic stroke, systemic embolism, or 7-day device/procedure-related events requiring major intervention
- Follow-up
- Up to 5 years
Methodological details2:1 assignment
- 2:1 assignment
Primary result
As reported in the abstract
- Primary safety endpoint, implant-attempted patients
- 1.0%
Further findings
| Outcome | LAAC | Control treatment | HR (95% CI) | |
|---|---|---|---|---|
| Disabling/fatal stroke (exploratory)Nominally less frequent with LAAC · exploratory analysis | 2.2% | 5.7% | 0.32 (0.10–1.05) | |
| 0.10.31310Hazard ratio (log scale) |
Conduct of the trial
- Withdrawal, LAAC
- 7.8%
- Withdrawal, control treatment
- 24.2%
- Follow-up, control patients
- median 876 days and 440.1 total patient-years
- Follow-up, LAAC patients
- median 1,768 days and 1,154.6 total patient-years
- Enrollment stopped early because of slow accrual, accentuated by the COVID-19 pandemic
- Fewer than the 34 events required to trigger the first planned interim analysis
Baseline characteristics
- Age
- 75 ± 8 years
- CHA2DS2-VASc score
- 4.6 ± 1.7
- Prior intracranial/subdural hemorrhage
- 34%
Implantation success
- Implantation success
- 97.8%
Safety
| Outcome | LAAC | Control treatment | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Major bleeding | 22.1% | 15.7% | 1.64 (0.96–2.81) | P = 0.067 | |
| 0.20.5125Hazard ratio (log scale) |
- Major bleeding: concentrated during the first 3 months
Pericardial effusions requiring intervention
- Pericardial effusions requiring intervention
- 3
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →